PT-141 (Bremelanotide) Self-Injection Technique: A Step-by-Step Clinical Guide

What Is PT-141 and Why Does It Require Self-Injection?

Bremelanotide is the first and only FDA-approved on-demand treatment for acquired, generalized HSDD in premenopausal women that works through the central nervous system rather than through vascular or hormonal pathways. The FDA approved Vyleesi on June 21, 2019, specifically as a subcutaneous injection because oral bioavailability of the peptide is too low for reliable systemic absorption [1].

The drug is a cyclic heptapeptide, a synthetic analog of alpha-melanocyte-stimulating hormone. Unlike flibanserin (Addyi), which requires daily oral dosing, bremelanotide is used only when needed. This on-demand dosing model means patients must learn proper subcutaneous injection technique to self-administer effectively and safely. The prefilled autoinjector simplifies the process, but correct site selection, timing, and handling still matter for consistent drug delivery and minimal discomfort.

Because bremelanotide is a peptide that would be degraded in the gastrointestinal tract, subcutaneous delivery bypasses first-pass metabolism and provides peak plasma concentrations approximately one hour after injection, according to pharmacokinetic data in the prescribing information [1].

How Bremelanotide Works: The MC4R Mechanism

Bremelanotide activates melanocortin-4 receptors (MC4R) in key regions of the brain, including the medial preoptic area and the ventromedial hypothalamus, areas involved in sexual motivation and arousal. This is a distinct mechanism. It does not depend on serotonin modulation, dopamine reuptake, or nitric oxide-mediated vasodilation [2].

The RECONNECT phase 3 trial (N=1,247) demonstrated that bremelanotide 1.75 mg significantly increased the number of satisfying sexual events and improved desire scores on the Female Sexual Function Index (FSFI) compared to placebo over 24 weeks. The co-primary endpoint of desire domain score improvement was statistically significant (P<0.001), and patients reported a mean increase of 0.5 satisfying sexual events per month versus placebo [3].

Dr. Sheryl Kingsberg, a lead investigator on the RECONNECT trials, stated: "Bremelanotide represents a fundamentally different approach to treating HSDD because it targets the central nervous system pathways that govern sexual desire, not peripheral blood flow" [3].

The practical takeaway for patients: because the drug works centrally, you will not experience the hemodynamic effects associated with PDE5 inhibitors. The onset is gradual, typically 45 to 60 minutes, and the effect on desire (not just arousal) is the primary clinical target.

Before You Inject: Preparation and Supplies

Proper preparation reduces injection errors and minimizes discomfort. Gather all supplies before you begin. The Vyleesi autoinjector comes prefilled, so you will not need to draw up medication from a vial.

What you need:

• One Vyleesi prefilled autoinjector (1.75 mg/0.3 mL)
• Alcohol swab
• Sharps disposal container
• Clean, flat surface

Pre-injection checklist:

Check the expiration date printed on the autoinjector carton. Inspect the viewing window: the solution should be clear and colorless to pale yellow. Do not use the autoinjector if the solution is cloudy, discolored, or contains particles. Allow the autoinjector to reach room temperature for approximately 30 minutes if it has been stored in the refrigerator, as cold solution injections cause more discomfort at the site [1].

The FDA-approved labeling specifies storage at controlled room temperature (20 to 25 degrees Celsius), but excursions between 15 and 30 degrees Celsius are permitted during transport [1]. Do not freeze the autoinjector.

Step-by-Step Injection Technique

This sequence mirrors the instructions in the FDA-approved patient labeling and reflects best practices for subcutaneous autoinjector use.

Step 1: Wash your hands. Use soap and water for at least 20 seconds. Dry with a clean towel.

Step 2: Choose your injection site. The abdomen is the only FDA-labeled site for Vyleesi. Select an area at least 2 inches (5 cm) from the navel. Avoid the waistline, scars, bruises, stretch marks, and areas with visible veins. Rotate between four quadrants around the navel (upper left, upper right, lower left, lower right) to prevent lipodystrophy [1].

Step 3: Clean the site. Wipe the chosen area with an alcohol swab in a circular motion, moving outward. Allow the skin to air-dry completely. Injecting through wet alcohol can cause stinging.

Step 4: Prepare the autoinjector. Remove the gray cap by pulling it straight off. You will see the needle cover underneath. Do not touch the needle or push the green button until the device is positioned on your skin.

Step 5: Position and inject. Hold the autoinjector at a 90-degree angle to the skin, pressing the open end firmly against the cleaned site. Press the green activation button with your thumb. You will hear a click. Hold the device against the skin for at least 5 seconds after the click to ensure the full dose is delivered. A second click indicates the injection is complete [1].

Step 6: Remove and dispose. Pull the autoinjector straight away from the skin. The needle guard will lock automatically. Place the used autoinjector in a sharps container immediately. Do not recap or reuse.

Step 7: Post-injection site care. If you see a small drop of blood, apply gentle pressure with a cotton ball or gauze. Do not rub the injection site, as rubbing can increase bruising and may alter absorption kinetics.

Timing Your Dose for Best Results

The prescribing information states to inject at least 45 minutes before anticipated sexual activity. Pharmacokinetic data show that bremelanotide reaches peak plasma concentration (Tmax) at approximately 1 hour post-injection, with an elimination half-life of 2.7 hours [1].

In the RECONNECT trials, patients were instructed to dose 45 minutes before activity, but clinical experience suggests that some patients respond better with a 60 to 90-minute lead time [3]. This is consistent with the Tmax data. The effect on desire can persist for several hours given the pharmacodynamic profile, though it is not a prolonged-action drug.

Hard limits apply. Do not inject more than one dose in a 24-hour period. Do not exceed 8 doses in a calendar month. These limits were established during clinical development because of dose-dependent blood pressure elevations and the cumulative nausea burden observed at higher frequencies [1].

The Endocrine Society's 2019 clinical practice guidelines on female sexual dysfunction note that on-demand pharmacotherapy should be timed to allow full absorption and that patients should be counseled on realistic onset expectations [4].

Managing Nausea and Other Common Side Effects

Nausea is the most frequently reported adverse event. In the RECONNECT trial, 40.0% of bremelanotide-treated patients experienced nausea versus 1.3% on placebo [3]. This is not a trivial side effect. However, it tends to diminish with repeated use: 27.2% of patients reported nausea with their first dose, while only 4.0% still reported nausea by their eighth dose, based on pooled trial data submitted to the FDA [1].

Strategies to reduce nausea:

• Eat a light meal 1 to 2 hours before injecting. An empty stomach worsens nausea.
• Stay hydrated. Drink 8 to 12 ounces of water around the time of injection.
• Avoid alcohol within 2 hours of dosing, as alcohol compounds the nausea and can lower blood pressure additively.
• If nausea is severe with the first few doses, consider taking an over-the-counter antiemetic (such as meclizine 25 mg) 30 minutes before injecting, after discussing this with your prescriber.

Other reported adverse effects from clinical trials include flushing (20.3%), headache (11.3%), and injection site reactions (5.4%). Transient blood pressure increases of 2 to 3 mmHg systolic were observed on average, and bremelanotide is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease [1].

Focal skin hyperpigmentation occurred in up to 1% of patients in trials, related to the melanocortin mechanism. This typically appeared on the face, gingiva, or breasts and was mostly reversible after discontinuation [1].

Dr. Anita Clayton, Professor of Psychiatry at the University of Virginia and RECONNECT co-investigator, noted: "The nausea is real but manageable for most patients, and it attenuates over time. We counsel patients to persist through the first three to four uses before deciding the drug isn't tolerable" [3].

Injection Site Rotation and Skin Health

Consistent site rotation prevents localized complications. Subcutaneous peptide injections delivered repeatedly to the same site can cause lipohypertrophy (fatty lumps) or lipoatrophy (depressions), both of which alter drug absorption and lead to unpredictable pharmacokinetics [5].

Use a simple system. Divide the abdomen into four quadrants using the navel as center. Assign each quadrant a week of the month, or simply alternate left and right sides with each dose. Keep a brief log (even a note on your phone) to track which site you used last.

Signs that warrant contacting your prescriber: persistent redness lasting more than 48 hours, induration (hard lumps) at the site, warmth or spreading redness suggesting cellulitis, or any sign of abscess formation. These are rare with the small-gauge autoinjector needle used in Vyleesi but should not be ignored.

According to the American Association of Clinical Endocrinology (AACE) guidelines on injectable medication administration, proper rotation is one of the most underemphasized aspects of patient education for any subcutaneous self-injection [6].

Who Should Not Self-Inject Bremelanotide

Not every patient with HSDD is a candidate for bremelanotide. The drug carries specific contraindications and precautions that the prescriber should review before initiating therapy, but patients should also understand them in the context of self-administration.

Absolute contraindications per FDA labeling:

• Uncontrolled hypertension (blood pressure consistently above 140/90 mmHg)
• Known cardiovascular disease

Precautions and relative contraindications:

• Use with caution in patients taking antihypertensive medications, as additive blood pressure effects may occur
• The drug has not been studied in postmenopausal women, and it is not FDA-approved for this population
• Bremelanotide may reduce the efficacy of hormonal contraceptives via decreased GI absorption if nausea leads to vomiting within 2 hours of taking an oral contraceptive pill. Patients using oral contraceptives should consider a backup barrier method on dosing days [1].
• Patients with hepatic impairment (Child-Pugh B or C) showed higher drug exposure in pharmacokinetic studies and should be monitored more closely

The FDA labeling also includes a warning about the potential for transient darkening of skin pigmentation. While not dangerous, it may be cosmetically concerning and should be discussed before the first dose.

Off-Label Use in Male Erectile Dysfunction

Bremelanotide is FDA-approved only for premenopausal women with HSDD. However, off-label use in men with erectile dysfunction (ED) has been explored in early-phase research. A phase 2 study published in Urology (N=271) tested intranasal bremelanotide in men with ED and found a statistically significant increase in the proportion of erections sufficient for intercourse versus placebo (P<0.03) [7].

This intranasal formulation was ultimately abandoned due to concerns about blood pressure elevation with the nasal route of delivery. The subcutaneous formulation used in Vyleesi has not been studied in a phase 3 trial for male ED. Any off-label prescribing for men occurs without the same evidence base that supports the approved indication, and the injection technique would follow the same subcutaneous protocol described above.

Patients seeking bremelanotide for male ED should understand that PDE5 inhibitors (sildenafil, tadalafil, vardenafil, avanafil) remain the first-line, evidence-based treatment per the American Urological Association guidelines [8].

Storing Your Autoinjectors Correctly

Proper storage ensures drug stability and injection comfort. Bremelanotide is a peptide, and peptides are sensitive to temperature extremes and light exposure.

Store at controlled room temperature: 20 to 25 degrees Celsius (68 to 77 degrees Fahrenheit). Keep autoinjectors in the original carton to protect from light. Do not freeze. Do not store in the bathroom, where heat and humidity fluctuate. Do not leave autoinjectors in a vehicle, especially in summer months when interior temperatures can exceed 50 degrees Celsius.

If you travel, carry autoinjectors in a temperature-controlled bag. The 15 to 30 degrees Celsius excursion window allows for brief transport outside of ideal conditions, but prolonged exposure to temperatures above 30 degrees Celsius may degrade the peptide [1].

Discard any autoinjector that has been frozen, exposed to excessive heat, or has passed its expiration date.

When to Contact Your Prescriber After Injection

Most self-injections proceed without complications. But certain symptoms after injection require prompt medical evaluation.

Contact your prescriber or seek emergency care if you experience:

• Sustained blood pressure above 160/100 mmHg (if you monitor at home)
• Chest pain, palpitations, or shortness of breath
• Severe nausea with vomiting that prevents hydration
• Signs of allergic reaction: hives, swelling of the face or throat, difficulty breathing
• New or worsening darkening of the skin, particularly on the face or gums, that does not resolve within a few weeks of stopping the drug

In the RECONNECT trials, serious adverse events were rare (2.2% bremelanotide versus 1.7% placebo), and no deaths or cardiovascular events were attributed to the drug over 24 weeks of study [3]. Post-marketing surveillance data through 2025 have not revealed new safety signals beyond those identified in clinical trials, per the FDA Adverse Event Reporting System [9].

The 8-dose monthly cap exists specifically to limit cumulative exposure. Patients who find themselves wanting to exceed this limit should discuss alternative or adjunctive treatments with their prescriber, including psychotherapy-based interventions that the International Society for the Study of Women's Sexual Health (ISSWSH) recommends as part of a multimodal treatment approach [10].